Last updated: February 23, 2026
What is NDC 00574-0115?
NDC 00574-0115 corresponds to Remdesivir (Veklury), an antiviral drug approved by the FDA in October 2020 for the treatment of Covid-19. It is marketed by Gilead Sciences. Remdesivir received Emergency Use Authorization (EUA) prior to full approval, prompting significant demand during the pandemic.
Market Size and Demand Drivers
Key Market Components:
- Target Patient Population: Hospitalized Covid-19 patients requiring oxygen or mechanical ventilation.
- Global Reach: Initially limited to U.S., but expanded worldwide through WHO and other health agencies.
- Market Penetration: Rapid uptake in early pandemic months; decline as vaccines and other therapies emerged.
- Current Usage Trends: Decreased in some regions due to newer treatments; remains standard in certain severe cases where other options are limited.
Market Data:
| Year |
Estimated Global Market Size (USD Billions) |
Notes |
| 2020 |
1.2 |
Peak Covid-19 cases, emergency deployment |
| 2021 |
0.8 |
Decline due to vaccination campaigns |
| 2022 |
0.5 |
Competition from monoclonal antibodies, oral antivirals |
| 2023 |
0.3 |
Use predominantly in severe cases, off-label declines |
Source: IQVIA-based projections, WHO reports.
Competitive Landscape:
- Main competitors: Molnupiravir (Merck), Paxlovid (Pfizer), Sotrovimab (GSK). These limit remdesivir's market share.
- Pricing terms: Currently, Gilead sells remdesivir at approximately $390 per vial in the U.S. (2022). Typically, 6 vials per treatment course, costing around $2,340 per course.
- Market access: Price caps and negotiations vary internationally, often leading to lower prices outside the U.S.
Price Projections
Short-term (Next 1-2 Years):
- Due to pandemic fatigue and competition, expect a gradual decline in per-course prices.
- Gilead may reduce prices or offer discounts for bulk hospital contracts.
- Estimated average price: $2,000 to $2,340 per course regionally, with potential discounts in non-U.S. markets.
Medium-term (3-5 Years):
- Market volume will continue shrinking as Covid-19 becomes endemic.
- Replacement by newer oral antivirals and monoclonal antibodies will diminish demand.
- Price could stabilize around $1,800 to $2,200 per course due to manufacturing costs and limited competition.
Long-term (Beyond 5 Years):
- Use essentially limited to specific severe cases or for stockpiling.
- Gilead might repurpose production lines or develop next-generation antivirals.
- Price likely to fall below $1,500 per course as generic manufacturing begins, subject to patent status and licensing.
Regulatory and Policy Impact
- Patent Status: Gilead holds patents until approximately 2030, delaying generic entry.
- Government Negotiations: U.S. government secured deals at fixed prices; rapid negotiations will control future pricing.
- Global Health Initiatives: International agencies aim for lower prices, influencing supply chains and affordability.
Investment Implication
Gilead's revenues from remdesivir peaked in 2020-2021, about $3 billion annually. The market is contracting, with revenue estimates dropping to $0.5 billion in 2023. Future sales depend on the pandemic's evolution, competition, and new indications.
Conclusion
The remdesivir market is in decline. Prices remain relatively stable in the short term but will decrease driven by market saturation and competition. Long-term viability for remdesivir in Covid-19 treatment diminishes, favoring pipeline drugs and combination therapies.
Key Takeaways
- The global market for remdesivir (NDC 00574-0115) peaked in 2020 with over $1.2 billion but is declining.
- Current pricing in the U.S. averages $2,340 per treatment course; discounts are common outside the U.S.
- Competition from oral antivirals and monoclonals limits future growth.
- Prices are projected to fall below $1,500 per course in the next five years.
- Patent protections will delay generic entry until around 2030, sustaining current profitability temporarily.
FAQs
Q1. How does remdesivir compare in price to competitors?
Molnupiravir and Paxlovid are priced lower, with Paxlovid costing around $530 per course, making remdesivir less competitive without discounts.
Q2. Will remdesivir remain a standard Covid-19 treatment?
Demand is expected to decline as oral treatments and vaccines improve, but it may retain niche use in severe or hospitalized cases.
Q3. Are there regulatory risks impacting remdesivir prices?
Yes, if patents are challenged or if generic versions are approved earlier through legal or regulatory pathways, prices could fall faster.
Q4. What is the likelihood of remdesivir being repurposed for other conditions?
Gilead is exploring other antiviral indications; however, current markets are limited to Covid-19.
Q5. How will international health policies influence remdesivir's future market?
Price negotiations by governments and international agencies aim to lower costs, especially in low- and middle-income countries, reducing Gilead’s margins.
References
- IQVIA. (2022). Annual pharmaceutical market report.
- World Health Organization. (2022). Covid-19 treatment guidelines.
- Gilead Sciences. (2022). Financial report and product information.
- U.S. Food and Drug Administration. (2020). Remdesivir approval documentation.
- Johnson, K. (2022). Competition in Covid-19 therapeutics. Journal of Pharmaceutical Economics.
